Sriram Ryali

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Palo Alto, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Barbara G. McClung, as attorney-in-fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Sriram Ryali

Form 4 holding Chief Financial Officer

CODEXIS, INC.

Security class
Common Stock
Shares / value
175,791
Estimated value
$370,638
Report date
01 Jan 2024
Price
$2.11
Ownership
Direct
Form 4 holding Chief Financial Officer

CODEXIS, INC.

Security class
Stock Option (Right to Buy)
Shares / value
314,125
Estimated value
Report date
01 Jan 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Financial Officer

Caribou Biosciences, Inc.

Security class
Option to purchase Common Stock
Shares / value
247,500
Estimated value
Report date
20 Feb 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Financial Officer

Eiger BioPharmaceuticals, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
143,000
Estimated value
Report date
11 Mar 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Sriram Ryali

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .